Pfizer triumphs at environmental awards

Pfizer has been recognised as a leader in environmental excellence at the recent Business Commitment to the Environment (BCE) awards. Twelve companies received recognition...

CORRECTION: MabThera recommended in Scotland

Scottish physicians are now able to prescribe MabThera (rituximab) on the NHS, following a positive recommendation by the Scottish Medicines Consortium (SMC). MabThera was...

GPs need swine flu guidance

A poll of GPs by has revealed that, so far, only 9% of GPs in the UK have been given regular, clear and concise...

Tamiflu discount for poorer countries

Roche is to provide its antiviral Tamiflu at a lower price to developing countries as part of a new initiative. Under the Tamiflu Reserves...

Viruses resistant to Tamiflu identified

Several cases of the H1N1 ‘swine flu’ virus have emerged that are resistant to antiviral drug Tamiflu (oseltaminvir). WHO has been informed by...

Novo Nordisk launches Victoza in UK

Novo Nordisk’s Victoza is now available for type 2 diabetes patients in the UK, following EU approval. Victoza is the first once-daily human Glucagon-like...

Novartis joins fight against malaria

Novartis has become the first healthcare company to join United Against Malaria (UAM), a pan-Africa campaign to end malaria-related deaths and suffering by 2015....

Best-selling drugs cheaper in Europe

European prices of 170 best-selling drugs averaged 40% less than US prices in 2008, recent research has revealed. Within Europe, it was found,...

Study confirms Cervarix efficacy

The largest efficacy trial of a cervical cancer vaccine has shown that Cervarix protects against the five most common cancer-causing virus types. The...

Positive CHMP opinion for Javlor

The CHMP has issued a positive opinion recommending EU marketing authorisation for Javlor from Laboratoires Pierre Fabre. The drug has been recommended for...

Latest articles

Promising Innovative Medicine designation for Novartis' targeted radioligand theragnostics in prostate cancer

Promising Innovative Medicine designation for Novartis’ targeted radioligand theragnostics in prostate cancer

Novartis has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation for 177Lu-PSMA-617, an investigational radioligand...
Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, demonstrated a significant improvement in...
AstraZeneca invests in Imperial College spin-off, VaxEquity

AstraZeneca invests in Imperial College spin-off VaxEquity

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisation of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Promising Innovative Medicine designation for Novartis' targeted radioligand theragnostics in prostate cancer

Promising Innovative Medicine designation for Novartis’ targeted radioligand theragnostics in prostate cancer

Novartis has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation for 177Lu-PSMA-617, an investigational radioligand...
UK market access and the opportunities for pharma

UK market access and the opportunities for pharma

The UK market access environment faces a time of change – the result of the convergence of several major drivers of reform. The COVID-19...
Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, demonstrated a significant improvement in...
Line of paper people with pills for a head. Image for Why do we need community pharmacy

Why do we need community pharmacy?

Dr Zubair Ahmed discusses the important role the community pharmacy plays in the sustainability of healthcare. Working as a GP, I saw first-hand how the...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription